Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer
Related Research units
Abstract
The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.
Bibliographical data
| Translated title of the contribution | Update Mammakarzinom 2022 Teil 5 – Brustkrebs in frühen Krankheitsstadien |
|---|---|
| Original language | English |
| ISSN | 0016-5751 |
| DOIs | |
| Publication status | Published - 03.2023 |
Comment Deanary
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).
| PubMed | 36908285 |
|---|
